A simple, 50/50 cash-to-PFE strategy with no automatic rebalancing: hold Pfizer stock half your capital and keep the other half in cash. Very conservative exposure, easy to understand, with no signals driving trades.

This strategy allocates money 50/50 between cash and Pfizer stock (PFE). The root step calls a cash-equal weighting, which means each component (cash and PFE) should have equal weight in the portfolio. Because there is only one stock listed, the plan effectively splits the total capital evenly: half in cash, half in PFE. There is no automatic rebalancing (rebalance: none). A 5% corridor width is noted, but it only matters if rebalancing were enabled—drift within 5% is allowed before a rebalance would be triggered. In short: you buy Pfizer and keep half of your money in cash, and you don’t automatically rebalance.

Conservative 50/50 cash-PFE with no rebalancing; simple, transparent exposure and a cash cushion to dampen drawdowns. Potentially lower volatility than the S&P 500 while still capturing Pfizer's upside.